Option chain shows key data for 's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for .

 (HRYU) Stock, Option Chain

Why It Matters

Earnings

Equities

News

Eurozone

Commodities

Markets

Trading Ideas

BKYI

EFSH

GLYC

HRYU

PGHL

SHPH

US Stocks Mixed; McDonald&#39;s Posts Upbeat Earnings

VFCorp.Shutterstock

Pre-Market Outlook

Movers

AMKR

AREB

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DBGI

EVOK

FFIV

GRDI

HLIT

IMRN

IVDA

LIXT

LTBR

QUBT

TMDX

VEEA

Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket

Caterpillar - logo

ACON

AIRE

ATNI

BMRN

BNAI

BPTS

BRFH

BRKL

CDTX

CSSE

CYCC

ESGL

FCFS

HUIZ

ILAG

JAKK

OPTN

ORGO

PCSA

POAI

PTSI

SGBX

SNBR

SPCB

STRA

ULBI

ZAPP

Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday&#39;s Mid-Day Session

Financial giants have made a conspicuous bearish move on JD.com. Our analysis of options history for JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) revealed 20 unusual trades.
Delving into the details, we found 30% of traders were bullish, while 45% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $170,335, and 16 were calls, valued at $2,348,235.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $27.5 to $41.0 for JD.com over the last 3 months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for JD.com's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of JD.com's whale activity within a strike price range from $27.5 to $41.0 in the last 30 days. 
<h3>JD.com 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735583436_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$8.15</td>
<td>$8.1</td>
<td>$8.1</td>
<td>$27.50</td>
<td>$486.0K</td>
<td>1.8K</td>
<td>1.2K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$8.4</td>
<td>$8.2</td>
<td>$8.3</td>
<td>$27.50</td>
<td>$415.0K</td>
<td>1.8K</td>
<td>1.7K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$6.65</td>
<td>$6.6</td>
<td>$6.6</td>
<td>$30.00</td>
<td>$330.0K</td>
<td>5.5K</td>
<td>500</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/20/25</td>
<td>$5.25</td>
<td>$5.15</td>
<td>$5.2</td>
<td>$32.50</td>
<td>$260.0K</td>
<td>1.9K</td>
<td>2.0K</td>
</tr>
<tr>
<td>JD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$5.15</td>
<td>$5.0</td>
<td>$5.15</td>
<td>$32.50</td>
<td>$257.5K</td>
<td>1.9K</td>
<td>503</td>
</tr>
</tbody>
</table>

<h3>About JD.com</h3>
JD.com is a leading e-commerce platform with its 2022 China GMV being similar to Pinduoduo (GMV not reported), on our estimate, but still lower than Alibaba. it offers a wide selection of authentic products with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
After a thorough review of the options trading surrounding JD.com, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Present Market Standing of JD.com</h3>
<ul>
<li>With a trading volume of 6,736,117, the price of JD is down by -1.94%, reaching $34.3.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 65 days from now.</li>
</ul>
<h3>What The Experts Say On JD.com</h3>
A total of 1 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $46.0.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has elevated its stance to Outperform, setting a new price target at $46. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest JD.com options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Spotlight on JD.com: Analyzing the Surge in Options Activity

Deep-pocketed investors have adopted a bullish approach towards Novo Nordisk (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in NVO usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 22 extraordinary options activities for Novo Nordisk. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 50% leaning bullish and 31% bearish. Among these notable options, 9 are puts, totaling $571,820, and 13 are calls, amounting to $1,045,859.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $45.0 to $170.0 for Novo Nordisk over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Novo Nordisk's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Novo Nordisk's whale trades within a strike price range from $45.0 to $170.0 in the last 30 days. 
<h3>Novo Nordisk Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735583431_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.0</td>
<td>$1.93</td>
<td>$1.94</td>
<td>$95.00</td>
<td>$397.7K</td>
<td>1.1K</td>
<td>2.1K</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$13.1</td>
<td>$13.05</td>
<td>$13.1</td>
<td>$87.50</td>
<td>$217.4K</td>
<td>69</td>
<td>205</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$34.75</td>
<td>$33.1</td>
<td>$33.6</td>
<td>$120.00</td>
<td>$165.8K</td>
<td>0</td>
<td>50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$5.1</td>
<td>$4.95</td>
<td>$4.96</td>
<td>$82.50</td>
<td>$99.2K</td>
<td>1.1K</td>
<td>201</td>
</tr>
<tr>
<td>NVO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$85.2</td>
<td>$83.65</td>
<td>$83.68</td>
<td>$170.00</td>
<td>$83.6K</td>
<td>10</td>
<td>10</td>
</tr>
</tbody>
</table>

<h3>About Novo Nordisk</h3>
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
After a thorough review of the options trading surrounding Novo Nordisk, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Novo Nordisk's Current Market Status</h3>
<ul>
<li>With a volume of 3,808,605, the price of NVO is down -1.21% at $86.31. </li>
<li>RSI indicators hint that the underlying stock may be oversold.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>What The Experts Say On Novo Nordisk</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $105.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from BMO Capital has decided to maintain their Outperform rating on Novo Nordisk, which currently sits at a price target of $105. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Novo Nordisk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Novo Nordisk's Options: A Look at What the Big Money is Thinking

Financial giants have made a conspicuous bearish move on Rivian Automotive. Our analysis of options history for Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) revealed 9 unusual trades.
Delving into the details, we found 22% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 3 were puts, with a value of $195,173, and 6 were calls, valued at $644,493.
<h3>Predicted Price Range</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $12.5 to $40.0 for Rivian Automotive over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Rivian Automotive stands at 17162.12, with a total volume reaching 9,535.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Rivian Automotive, situated within the strike price corridor from $12.5 to $40.0, throughout the last 30 days.
<h3>Rivian Automotive Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735583426_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$0.67</td>
<td>$0.65</td>
<td>$0.66</td>
<td>$40.00</td>
<td>$329.8K</td>
<td>28.7K</td>
<td>5.0K</td>
</tr>
<tr>
<td>RIVN</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$6.45</td>
<td>$6.35</td>
<td>$6.35</td>
<td>$17.50</td>
<td>$93.3K</td>
<td>4.8K</td>
<td>300</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.55</td>
<td>$4.35</td>
<td>$4.3</td>
<td>$12.50</td>
<td>$85.5K</td>
<td>6.8K</td>
<td>199</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$4.35</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$12.50</td>
<td>$68.4K</td>
<td>6.8K</td>
<td>372</td>
</tr>
<tr>
<td>RIVN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.34</td>
<td>$1.24</td>
<td>$1.3</td>
<td>$12.50</td>
<td>$64.8K</td>
<td>51.5K</td>
<td>506</td>
</tr>
</tbody>
</table>

<h3>About Rivian Automotive</h3>
Rivian Automotive Inc designs, develops, and manufactures category-defining electric vehicles and accessories. In the consumer market, the company launched the R1 platform with the first generation of consumer vehicles: the R1T, a two-row, five-passenger pickup truck, and the R1S, a three-row, seven-passenger sport utility vehicle (SUV).
Having examined the options trading patterns of Rivian Automotive, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Rivian Automotive Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 11,274,025, with RIVN's price down by -1.98%, positioned at $13.38.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 51 days.</li>
</ul>
<h3>Expert Opinions on Rivian Automotive</h3>
1 market experts have recently issued ratings for this stock, with a consensus target price of $16.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Baird has revised its rating downward to Neutral, adjusting the price target to $16. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Rivian Automotive with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

RIVN

Check Out What Whales Are Doing With RIVN

Former President Donald Trump has been in the spotlight for decades for his business ventures, political activities and legal matters. Less known is his involvement with cryptocurrency, where he has built a multimillion-dollar portfolio and profited from selling some of his tokens. Here&#8217;s an updated overview of the tokens Trump holds, <a href="https://intel.arkm.com/explorer/entity/donald-trump">according to Arkham databases</a>.
The TROG token is the largest holding in Trump&#8217;s portfolio, with 210.345 billion tokens valued at approximately $4.5 million. TROG's token distribution strategy involves allocating 50% of its tokens to celebrity wallets, sparking widespread discussion in the crypto community. This token saw a <a href="https://www.benzinga.com/markets/cryptocurrency/24/10/41603596/donald-trumps-crypto-portfolio-gains-over-429-000-in-october-as-trump-themed-tokens-rally">value surge right before elections</a> from $1.67 million in late September to about $2.58 million by the end of October.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/elon-musk-told-the-u-n-if-they-could-show-a-plan-for-ending-world-hunger-hed-donate-6-billion-i-will-sell-tesla-stock-right-now-and-do-it">Elon Musk Told The U.N. If They Could Show A Plan For Ending World Hunger He'd Donate $6 Billion – ‘I Will Sell Tesla Stock Right Now And Do It'</a></li>
<li>Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a></li>
</ul>
Trump&#8217;s portfolio also includes a substantial investment in Ethereum (ETH) and Wrapped Ethereum (WETH). He holds approximately 500 ETH and WETH, valued at roughly $1.6 million based on ETH's current price of $3,383.74 at time of writing. These tokens primarily stem from the Trump Digital Trading Cards NFT collection, which featured 45,000 NFTs priced at $99 each and used Trump's likeness and branding. Through royalties, Trump has reportedly received over 1,700 ETH from this project. In late 2023, <a href="https://www.benzinga.com/markets/cryptocurrency/24/01/36743035/donald-trump-sold-2-4-million-ethereum-smart-move-or-big-mistake">Trump sold 1,075 ETH</a>, transferring the funds to Coinbase and generating around $2.4 million in profits.
Another significant asset in his portfolio is MAGA Coin (TRUMP), a meme coin launched last summer to champion Trump's political agenda and fund-aligned charities. Upon its creation, 580,000 TRUMP tokens were sent to his wallet, initially worth only a few thousand dollars at a valuation below $0.01 per token. By March, the token&#8217;s price surged to $11.56, pushing the value of his holdings to over $6.7 million. However, the current price has dropped to approximately $1.46 per token, bringing the total worth of his MAGA Coin holdings to around $961.62.
Trending: Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a>
TROG, ETH, WETH and TRUMP account for approximately $8.7 million of Trump's $9.7 million crypto portfolio. Additionally, he holds over 50 other tokens with a significant chunk of memecoins.
The largest is CONAN, a meme coin named after a special forces dog famed for its role in the 2019 raid targeting Abu Bakr al-Baghdadi. The creators, affiliated with the team behind TRUMP, sent 20 billion CONAN tokens to Trump&#8217;s wallet at the project&#8217;s launch in February. The tokens were worth $40,000 at launch but have since depreciated to around $23,400.&nbsp;
Although not widely publicized, Trump&#8217;s crypto portfolio offers a peculiar glimpse into the cryptocurrency community and his financial interests. The eclectic nature of his holdings provides insight into both the digital asset market and Trump&#8217;s investment strategies. As blockchain transactions are publicly accessible, anyone can monitor Trump&#8217;s portfolio to observe all inflows, outflows and new tokens he acquires.
This story was previously reported but updated with current crypto holdings.
Read Next:
<ul>
<li>Grant Cardone once said "I love games and the chance to be a winner." You can be a winner too and join the <a href="https://www.benzinga.com/money/gameflip">$272B global games market by getting access into this asset market with just $0.55/share.</a></li>
<li>Coinbase&#8217;s latest promo gets you up to $200 in crypto (Seriously!)— <a href="http://coinbase-consumer.sjv.io/m5ALXy">Here's everything you need to know to take advantage of this offer.</a></li>
</ul>
Image from Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Donald Trump's $9.9 Million Crypto Portfolio: Over 50% Growth Since September – How Many Cryptocurrencies Does Trump Own?

Shares of Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) are trading <a href="https://www.benzinga.com/quote/MU/news">lower on Monday</a>, and they could be about to break support.
Stocks that break support tend to trend lower. This is why Micron is our Stock of the Day.
Many people overcomplicate technical analysis. But it is simply the study of supply and demand.
If a stock is trending lower, it is because there isn't enough demand (buy orders) to absorb all of the supply (sell orders). As a result, investors and traders who wish to sell are forced to offer their shares at a discount to attract buyers.
This forces the stock into a downtrend.
Read Also: <a href="https://www.benzinga.com/24/12/42725647/markets-will-close-for-president-jimmy-carters-state-funeral-what-you-need-to-know">Markets Will Close For President Jimmy Carter&#8217;s State Funeral: What You Need To Know</a>
When a stock drops to a support level, the dynamic changes. There is more than enough demand to absorb all of the supply. Those who want to sell can do so without the fear of pushing the price lower.
As you can see on the chart, Micron has support at around $86.60. This level has been support since August.
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="555" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30130625/mu-1024x555.png" alt="" class="wp-image-711877" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30130625/mu-1024x555.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30130625/mu-300x162.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30130625/mu-768x416.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/30130625/mu.png 1492w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Support levels can stay intact for an extended period of time due to seller's remorse. There are people who sold the stock while it was at support that regretted doing so when the price rallied soon after.
Some of them decide they made a mistake and vow to repurchase their shares if they can do so at the same price they were sold for. As a result, if the stock eventually reverses and drops back to their selling price, they place buy orders.
If there are enough of these buy orders, it will form support at the same price that had been support before.
If a stock trades and stays below the support level, traders say the support has been broken. This illustrates an important supply and demand dynamic.
This indicates that the traders and investors who established support with their buy orders have either completed their purchases or canceled their orders. In either case, they are no longer active in the market.
This could set the stage for a move lower and that may be about to happen with Micron. People who wish to sell may be forced once again to offer their shares at a discount to attract buyers.
This may force the stock into a new downtrend.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42726550/stanley-druckenmiller-loaded-up-on-regional-banks-ahead-of-trumps-election-win">Stanley Druckenmiller Loaded Up On Regional Banks Ahead Of Trump&#8217;s Election Win</a></li>
</ul>
Photo by NPS_87 on Shutterstock

Technicals

Tech

Stock Of The Day: Micron At Risk Of Breaking Key Support

Guidance

LAES

SEALSQ Says Co Projecting Cash Position In Excess Of $85M By Jan. 3, 2025

Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) completed acquiring Israeli startup<a target="_blank" href="https://www.run.ai/blog/run-ai-joins-nvidia" rel="noreferrer noopener"> </a><a target="_blank" href="https://www.run.ai/blog/run-ai-joins-nvidia" rel="noreferrer noopener">Run:ai</a>, marking its most significant in Israel since its $6.9 billion Mellanox Technologies deal in 2020.
The startup pledged to help customers maximize their <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">AI infrastructure</a> by providing flexible, efficient, and highly utilized GPU systems. These solutions will be available across various platforms, including on-premises setups, cloud-based native solutions, and Nvidia DGX Cloud, which was co-developed with leading cloud service providers.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42725756/xiaomi-evs-to-access-charging-networks-of-nio-xpeng-and-li-auto" rel="noreferrer noopener">Xiaomi Expands EV Charging Options, Partners with NIO, XPeng, and Li Auto for Greater Network Access</a>
Aligned with its open-platform philosophy, Run:ai, now part of Nvidia, will continue empowering AI teams to select the tools, platforms, and frameworks that best meet their needs. It plans to strengthen partnerships and collaborate with the ecosystem to deliver diverse AI solutions and platform options.
Additionally, the startup intends to open-source its Run:ai software, enabling the broader AI community to accelerate innovation. While supporting only Nvidia GPUs, the open-source initiative aims to expand compatibility across the entire AI ecosystem.
In April, Nvidia <a target="_blank" href="https://www.benzinga.com/government/24/04/38430747/nvidia-bolsters-ai-management-capabilities-purchases-israeli-firm-run-ai-for-roughly-700m" rel="noreferrer noopener">shared plans to</a> acquire Run:ai, reportedly for around $600 million &#8211; $700 million, and integrate it into its operations in Israel, which employed ~4,000 people across seven R&amp;D centers.
However, the deal drew regulatory scrutiny from&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/11/41685490/nvidias-run-ai-acquisition-draws-european-regulatory-scrutiny-on-competition-concerns" rel="noreferrer noopener">the European Commission</a> over possible anticompetitive concerns.
Nvidia stock surged over 190% year-to-date. The company is eying robotics as its next growth catalyst and plans to launch Jetson Thor computers for <a target="_blank" href="https://www.benzinga.com/media/24/12/42721414/nvidia-targets-robotics-as-next-big-opportunity-amid-rising-ai-rivalry" rel="noreferrer noopener">humanoid robots in 2025</a>. Tesla Inc plans to start <a target="_blank" href="https://www.benzinga.com/media/24/11/41984426/nvidia-powers-teslas-humanoid-robots-with-new-ai-tech-heres-what-to-expect-in-2025" rel="noreferrer noopener">limited production of</a> its humanoid robot, Optimus, by late 2025, aiming for broader commercial availability in 2026. Nvidia supplies essential technology components to power Tesla&#8217;s robotics efforts.
Investors can gain exposure to Nvidia through VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) and Fidelity MSCI Information Technology Index ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTEC#NYSE">FTEC</a>).
Price Actions: NVDA stock is up 1.8% at $139.48 at the last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/24/12/42686698/meta-settles-israeli-job-ad-discrimination-case-for-1-million-report" target="_blank" rel="noreferrer noopener">Meta Settles Israeli Job Ad Discrimination Case For $1 Million: Report</a></li>
</ul>
Image via Shutterstock.

FTEC

NVDA

Nvidia Completes Run:ai Buyout: Details

At a strategy meeting featuring Alphabet Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) executives, CEO Sundar Pichai addressed key 2025 topics, including artificial intelligence, <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">competition and regulatory pressure</a>.
"The stakes are high," Pichai said at the Dec. 18 gathering, as <a href="https://www.cnbc.com/2024/12/27/google-ceo-pichai-tells-employees-the-stakes-are-high-for-2025.html">reported </a>by CNBC. "I think 2025 will be critical. I think it's really important we internalize the urgency of this moment and need to move faster as a company."
Pichai and other Alphabet leaders convened wearing ugly Christmas sweaters. Employees attended in person and watched virtually. CNBC obtained audio of the meeting.
Pichai said the company needs to focus on solving user problems and unlocking the benefits of AI for users. The Mountain View, California-based company also intends to launch several AI features in the first half of 2025, he noted. 
The comments come as the Department of Justice pushes Alphabet to divest Google Chrome to end <a href="https://www.benzinga.com/tech/24/11/42105079/googles-unlawful-behavior-stifles-market-entry-for-rivals-doj-says-alphabet-must-sell-chrome-to-end-search-monopoly">an alleged search monopoly</a>.
"It's not lost on me that we are facing scrutiny across the world,&#8221; Pichai said. &#8220;It comes with our size and success. It's part of a broader trend where tech is now impacting society at scale. So more than ever, through this moment, we have to make sure we don't get distracted."
Read Also: <a href="https://www.benzinga.com/news/earnings/24/10/41611263/alphabet-q3-earnings-highlights-revenue-beat-eps-beat-google-cloud-up-35-momentum-across-the-compan">Alphabet Q3 Earnings Highlights: Revenue Beat, EPS Beat, Google Cloud Up 35%, &#8216;Momentum Across The Company Is Extraordinary&#8217;</a>
Alphabet's search dominance with its Google brand also faces pressure from generative AI and new competition. Google's Gemini app, which uses AI to provide search results, could be one of the company's biggest focuses for 2025.
Pichai said "building big, new business" was among the top 2025 priorities, which includes the Gemini app.
"With the Gemini app, there is strong momentum, particularly over the last few months," Pichai said. "But we have some work to do in 2025 to close the gap and establish a leadership position there as well."
Pichai compared Gemini to competitors like OpenAI, acknowledging that the company is playing catch-up on several AI fronts.
"In history, you don't always need to be first, but you have to execute well and really be the best in class as a product. I think that's what 2025 is all about."
Pichai also asked for more scrappiness from the company's more than 180,000 employees.
"In early Google days, you look at how the founders built our data centers, they were really really scrappy in every decision they made. Often, constraints lead to creativity. Not all problems are always solved by headcount."
Price Action: Alphabet stock is down 1% to $192.15 on Monday versus a 52-week trading range of $131.55 to $202.88. Alphabet stock is up 37.6% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/tech/24/11/42143676/which-magnificent-7-stock-should-doj-target-next-benzinga-poll-finds-over-50-say">Which Magnificent 7 Stock Should DOJ Target Next? Benzinga Poll Finds Over 50% Say&#8230;</a></li>
</ul>
Image: Shutterstock

GOOG

GOOGL

Alphabet CEO Pichai Warns Employees Of High Stakes 2025: 'We Are Facing Scrutiny Across The World'

Macro Economic Events

WIIM

Economics

Natural gas is higher amid reports of cold January weather forecasts.

IBKR

CNBC Halftime Report Final Trades: Nvidia, Goldman Sachs, Interactive Broker, Jefferies Financial

<a href="https://www.benzinga.com/personal-finance/24/10/41387612/medicare-trust-fund-under-fire-critics-accuse-vp-harris-of-highway-robbery-for-allegedly-violati">Medicare </a>is again making waves for retirees and this time it&#8217;s because of significant cost increases for 2025. In a recent blog post, personal finance expert Suze Orman broke down the numbers, clarifying that planning is more crucial than ever for anyone relying on Medicare in their retirement years.
Starting with Medicare Part B, which covers doctor visits and various medical tests, the monthly premium is going up. According to the Centers for Medicare &amp; Medicaid Services (CMS), the standard cost will rise from $174.70 in 2024 to $185 in 2025, a 10.30% increase.&nbsp;
Don't Miss:
<ul>
<li>The average American couple has saved this much money for retirement —<a href="http://www.benzinga.com/money/smartasset"> How do you compare</a>?</li>
<li>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"> The percentage may shock you</a>.</li>
</ul>
If you&#8217;re an individual earning less than $106,000 annually (or a couple making under $212,000), you&#8217;ll pay this standard premium.&nbsp;
However, higher-income individuals will face even bigger charges, with premiums for the wealthiest enrollees possibly reaching as high as $628.90 per month. And remember, Medicare premiums are per person – there&#8217;s no family plan option, so couples will see their bills double. This is based on CMS&#8217;s 2025 Medicare parts A &amp; B premiums and deductibles report.
If you delay Social Security benefits, you must arrange direct payments for these premiums. According to a report by the Kaiser Family Foundation, some Medicare Advantage plans may offer partial rebates on Part B premiums, averaging $30 per month to help offset these costs.&nbsp;
See Also: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die."<a href="https://www.benzinga.com/money/warren-buffet-make-money-when-you-sleep"> Here&#8217;s how you can earn passive income with just $100.</a>
But it's not just premiums that are increasing. As stated on Medicare's website, the Medicare Part B deductible also rises slightly, from $245 in 2024 to $257 in 2025. Once that's paid, enrollees are still on the hook for 20% of Part B costs unless they've opted for supplemental insurance, like Medigap.&nbsp;
These gaps in coverage are a big reason nearly half Medicare enrollees are now relying on Medigap to cover out-of-pocket expenses.
Hospital stays under Medicare Part A bring their own financial challenges. While most people pay no monthly premium, the deductible for inpatient hospital care will climb to $1,632 in 2025, up from $1,600.&nbsp;
This deductible covers the first 60 days of a hospital stay. After that, costs skyrocket – enrollees will pay $419 daily for days 61 through 90. Once you reach day 150, Medicare stops covering your stay entirely, which can leave retirees facing massive out-of-pocket expenses for extended hospital stays.
Trending: Many are using retirement income calculators to check if they&#8217;re on pace —<a href="https://www.benzinga.com/money/how-do-i-calculate-my-retirement-income-adv"> here&#8217;s a breakdown on what&#8217;s behind this formula.</a>
Skilled nursing care under Medicare isn't free, either. For the first 20 days, Medicare covers the full cost. Starting on day 21, you'll be responsible for $209.50 per day. After 100 days, you're on the hook for all costs. With 70% of retirees likely to need long-term care at some point, these limits make having a plan for potential nursing home or rehab facility stays essential.
For prescription drug coverage, there's a bit of relief. Enrollees in Original Medicare must purchase a separate Part D plan with an average monthly premium of $40. Those in Medicare Advantage plans often have drug coverage bundled in.&nbsp;
The bright spot is the introduction of a $2,000 out-of-pocket cap on prescription drug costs in 2025. This cap will offer <a href="https://www.benzinga.com/personal-finance/24/09/40714364/survive-anything-kevin-oleary-claims-you-need-5-million-in-savings-heres-how-you-can-reach-that-">significant savings</a> to the 57% of Medicare Part D enrollees facing high drug costs.
When deciding between Original Medicare and Medicare Advantage, out-of-pocket costs must be considered. Original Medicare gives retirees more flexibility in choosing providers but doesn't have a maximum limit on annual out-of-pocket expenses, making Medigap insurance essential for managing those costs.&nbsp;
On the other hand, Medicare Advantage plans have out-of-pocket yearly limits of $9,350 for in-network care and $14,000 for out-of-network care in 2025. These plans also often include co-pays for various services, but the built-in cost caps make them an increasingly popular option for those looking to avoid unpredictable health care bills.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li><a href="https://www.benzinga.com/money/62-years-old-with-1-mil-saved">I&#8217;m 62 Years Old And Have $1.2 Million Saved. Is This Enough to Retire Stress-Free?</a></li>
</ul>

Personal Finance

Suze Orman Warns: 'Medicare Doesn't Cover Everything' – Why You Need $2,000 For Drugs And $1,676 For Hospital Costs In 2025

In the last three months, 9 analysts have published ratings on Legend Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LEGN#NASDAQ">LEGN</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $79.0, a high estimate of $86.00, and a low estimate of $73.00. This current average reflects an increase of 1.13% from the previous average price target of $78.12. 
<img src="https://www.benzinga.com/files/images/story/2024/1735581622_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Legend Biotech. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Rick Bienkowski</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Leonid Timashev</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$86.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
<tr>
<td>Qize Ding</td>
<td>Redburn Atlantic</td>
<td>Announces</td>
<td>Buy</td>
<td>$86.00</td>
<td>-</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$73.00</td>
<td>$73.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Legend Biotech. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Legend Biotech compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Legend Biotech's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
For valuable insights into Legend Biotech's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/LEGN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Legend Biotech analyst ratings.</a>
<h2>Discovering Legend Biotech: A Closer Look</h2>
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's lead product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
<h3>Legend Biotech's Financial Performance</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Legend Biotech displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 66.86%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Legend Biotech's net margin is impressive, surpassing industry averages. With a net margin of -78.23%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Legend Biotech's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -11.02%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Legend Biotech's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.09%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.31, Legend Biotech adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

LEGN

Breaking Down Legend Biotech: 9 Analysts Share Their Views

8 analysts have shared their evaluations of EastGroup Props (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EGP#NYSE">EGP</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for EastGroup Props, revealing an average target of $194.75, a high estimate of $209.00, and a low estimate of $180.00. This current average represents a 0.89% decrease from the previous average price target of $196.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1735581615_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A comprehensive examination of how financial experts perceive EastGroup Props is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stephen Byrd</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$180.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>William Crow</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$200.00</td>
<td>$185.00</td>
</tr>
<tr>
<td>Ki Bin Kim</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$186.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Blaine Heck</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$199.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Michael Carroll</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$186.00</td>
<td>$186.00</td>
</tr>
<tr>
<td>Richard Anderson</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$209.00</td>
<td>$209.00</td>
</tr>
<tr>
<td>Brendan Lynch</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$193.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>Steve Sakwa</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$204.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to EastGroup Props. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of EastGroup Props compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for EastGroup Props's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of EastGroup Props's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EGP/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on EastGroup Props analyst ratings.</a>
<h2>About EastGroup Props</h2>
EastGroup Properties Inc is an equity real estate investment trust. It is engaged in the development, acquisition, and operation of industrial properties in Sunbelt markets throughout the United States, predominantly in the states of Florida, Texas, Arizona, California, and North Carolina. The company manages a portfolio of industrial properties. The vast majority of these properties are multi-tenant business distribution buildings that provide large warehousing and office space for customers. The company derives its revenue in the form of rental income.
<h3>EastGroup Props's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining EastGroup Props's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.16% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Real Estate sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: EastGroup Props's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 33.88% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): EastGroup Props's ROE excels beyond industry benchmarks, reaching 1.97%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): EastGroup Props's ROA excels beyond industry benchmarks, reaching 1.17%. This signifies efficient management of assets and strong financial health.
Debt Management: EastGroup Props's debt-to-equity ratio is below the industry average. With a ratio of 0.58, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

The Analyst Verdict: EastGroup Props In The Eyes Of 8 Experts

Chimerix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMRX#NASDAQ">CMRX</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Chimerix, revealing an average target of $9.75, a high estimate of $11.00, and a low estimate of $6.00. Consistency is reflected as the current average remains at the same level as the previous average price target. 
<img src="https://www.benzinga.com/files/images/story/2024/1735581609_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The standing of Chimerix among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$6.00</td>
<td>$6.00</td>
</tr>
<tr>
<td>Edward White</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Chimerix. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Chimerix compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Chimerix's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Chimerix's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/CMRX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Chimerix analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Chimerix</h2>
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.
<h3>Financial Milestones: Chimerix's Journey</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Revenue Growth: Over the 3 months period, Chimerix showcased positive performance, achieving a revenue growth rate of 136.36% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Chimerix's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -87996.15%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Chimerix's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -15.7%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -13.57%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Chimerix's debt-to-equity ratio is below the industry average. With a ratio of 0.0, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CMRX

A Glimpse Into The Expert Outlook On Chimerix Through 4 Analysts

U.S. stocks traded lower midway through trading, with the Nasdaq Composite dipping more than 100 points on Monday.
The Dow traded down 0.61% to 42,725.52 while the NASDAQ fell 0.58% to 19,608.47. The S&amp;P 500 also fell, dropping, 0.59% to 5,935.35.
Check This Out: <a href="https://www.benzinga.com/24/12/42720315/this-analyst-with-82-accuracy-rate-sees-around-28-upside-in-apple-here-are-5-stock-picks-for-last-week-from-wall-streets-most-accurate-analysts">This Analyst With 82% Accuracy Rate Sees Around 28% Upside In Apple &#8211; Here Are 5 Stock Picks For Last Week From Wall Street&#8217;s Most Accurate Analysts</a>
Leading and Lagging Sectors Energy shares fell by just 0.6% on Monday.
In trading on Monday, consumer discretionary shares dipped by 2.2%.
Top Headline
The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Cytek Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTKB#NASDAQ">CTKB</a>) shares shot up 6% to $6.79. Cytek Biosciences announced a $50 million stock buyback program for 2025.</li>
<li>Shares of Emergent BioSolutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EBS#NYSE">EBS</a>)got a boost, surging 13% to $9.36. HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiated coverage on Emergent BioSolutions with a Buy rating and announced a price target of $15.</li>
<li>Hesai Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) shares were also up, gaining 9% to $14.69. Hesai Technology said it delivered more than 100,000 Lidar units during December.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Quantum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QMCO#NASDAQ">QMCO</a>) shares dropped 20% to $56.60.</li>
<li>Shares of Traws Pharma, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRAW#NASDAQ">TRAW</a>) were down 39% to $8.25. Traws Pharma entered into agreements to raise up to $72.6m from healthcare institutional investors to advance Tivoxavir Marboxil development.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) was down, falling 28% to $0.4301. On Sunday, the company disclosed a public offering of 16.13 million shares of common stock or pre-funded warrants at $0.31 per share.</li>
</ul>
Commodities In commodity news, oil traded up 1% to $71.32 while gold traded down 0.6% at $2,615.80.
Silver traded down 1.5% to $29.505 on Monday, while copper fell 0.7% to $4.0930.
Euro zone
European shares were mostly lower today. The eurozone's STOXX 600 fell 0.65%, Germany's DAX fell 0.38% and France's CAC 40 fell 0.58%. Spain's IBEX 35 Index rose 0.01%, while London's FTSE 100 fell 0.62%.
Asia Pacific Markets
Asian markets closed mostly lower on Monday, with Japan's Nikkei 225 falling 0.96%, China's Shanghai Composite Index gaining 0.21%, Hong Kong's Hang Seng Index falling 0.24% and India's BSE Sensex dipping 0.57%.
Economics
<ul>
<li>The Chicago PMI fell to 36.9 in December from 40.2 in November and missing market estimates of 42.5.</li>
<li>U.S. pending home sales increased 2.2% month-over-month in November, following a revised 1.8% gain in October and above market estimates of a 0.7% increase.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/24/12/42720878/top-3-tech-stocks-that-may-fall-off-a-cliff-this-quarter">Top 3 Tech Stocks That May Fall Off A Cliff This Quarter</a></li>
</ul>

Intraday Update

CTKB

HSAI

QMCO

TRAW

Crude Oil Gains 1%; Chicago PMI Falls In December

Former President Jimmy Carter died Sunday at the age of 100. While in office, Carter led the country through challenging times that included economic turmoil, the bailout of a legacy automaker and <a href="https://www.benzinga.com/movers-shakers/24/12/42716329/jimmy-carter-the-39th-us-president-who-championed-human-rights-and-peace-in-the-middle-east-had-died">an energy crisis.&nbsp;&nbsp;</a>
Carter — elected 39th President of the United States in 1976 — leaves behind a legacy of diplomacy and <a href="https://www.benzinga.com/24/12/42716729/jimmy-carter-to-receive-state-funeral-trump-calls-him-truly-a-good-man-biden-mourns-loss-of-extraordinary-leader">humanitarian work</a>. During Carter's presidency, the nation weathered tough economic conditions including rising inflation and high interest rates which contributed to his defeat in 1980. 
Read Next: <a href="https://www.benzinga.com/24/12/42700819/investors-bet-on-milei-the-argentina-trade">Milei&#8217;s Economic Chainsaw Slashes Inflation As Argentine Stocks Explode 175%</a>&nbsp;
Inflation: According to <a href="https://www.bls.gov/opub/mlr/2014/article/one-hundred-years-of-price-change-the-consumer-price-index-and-the-american-inflation-experience.htm">data from</a> the U.S. Bureau of Labor Statistics, Carter's administration saw the highest average year-over-year inflation rate of all U.S. presidents, at 9.9%. By the end of his presidency, inflation had surged to more than 13%.&nbsp;
Carter appointed Paul Volcker as chairman of the Federal Reserve Board in 1978 to combat the rising inflation. Volcker enacted a policy of dramatically increasing interest rates to slow economic activity and curb rising prices. This led to consumer loan interest rates as high as 18% by 1980, <a href="https://billofrightsinstitute.org/essays/jimmy-carter-and-the-malaise-speech">per the</a> Bill of Rights Institute.  
The combination of inflation and high interest rates led to "stagflation." It also pushed the economy into a recession as Carter ran for reelection in 1980. Ultimately, Carter lost the election to former President Ronald Regan.  
Chrysler: In 1980, Detroit automaker Chrysler was on the verge of bankruptcy as the country faced high unemployment and economic stagnation. To avoid job losses and further damage to the economy, Carter signed the Chrysler Corporation Loan Guarantee Act on Jan. 7, 1980, which provided $1.5 billion in loan guarantees, as <a href="https://www.npr.org/2008/11/12/96922222/examining-chryslers-1979-rescue">reported</a> by NPR.  
The Chrysler loan guarantee rescued the company from bankruptcy, stabilized the auto industry and saved thousands of jobs. This marked a shift toward more direct government involvement in the economy.  
The Carter administration faced criticism from opponents of the Chrysler bailout. And Chrysler eventually filed for bankruptcy in 2009. It was bought by Fiat later that year. 
Fiat Chrysler Automobiles N.V. repaid $12.5 billion of Chrysler's government loans and was renamed Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) which continues to operate today.
Energy Crisis: Carter also led the U.S. through a major energy crisis during his term in office. The Iranian Revolution in 1979 led to a significant drop in global oil production. Oil prices spiked from $13 per barrel in mid-1979 to $34 per barrel in mid-1980, <a href="https://www.energypolicy.columbia.edu/jimmy-carters-energy-policy-legacy/">according</a> to the Center for Global Energy Policy.  
Drivers waited in long lines at gas stations amid fuel shortages in the summer of 1979 and Carter responded with calls for energy conservation and alternative energy development.&nbsp;
"Our decision about energy will test the character of the American people and the ability of the president and the Congress to govern. This difficult effort will be the ‘moral equivalent of war' — except that we will be uniting our efforts to build and not destroy," Carter said in a speech on the energy crisis.&nbsp;
He encouraged energy conservation and efficiency and created the Department of Energy to centralize energy policy. Carter's focus on energy efficiency led to improvements in household appliances, with programs like the Appliance Standards Program, and his emphasis on renewable energy laid the groundwork for future developments in solar and other alternative energy sources. 
Carter even had 32 solar thermal panels installed on the White House roof to underscore the administration&#8217;s commitment to renewable energy and reduce reliance on fossil fuels.
When the panels were unveiled, Carter <a href="https://www.newyorker.com/news/daily-comment/jimmy-carter-green-energy-visionary?utm_source=chatgpt.com">predicted</a> renewable energy would be critical to the future of the United States.
By 1986, under the Reagan administration, the solar panels were removed and funding for renewable energy initiatives were significantly reduced. 
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/legal/24/12/42687945/zelle-became-a-gold-mine-for-fraudsters-consumer-financial-protection-bureau-lawsuit">&nbsp;&#8216;Zelle Became A Gold Mine For Fraudsters&#8217;: Consumer Financial Protection Bureau Lawsuit</a></li>
</ul>
Image: Shutterstock.

Politics

Global

STLA

Former President Jimmy Carter's Business Legacy Includes Chrysler Rescue, High Interest Rates, Energy Crisis

According to Rosenblatt analyst Barton Crockett, Netflix Inc&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) performance on Christmas Day <a target="_blank" href="https://www.benzinga.com/topic/streaming" rel="noreferrer noopener">streaming</a> two NFL games bolstered the notion of more major sports migrating over time to streaming.
He found it positive for disruptive, sports-linked streamers, including Netflix and Amazon.Com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), and challenging for traditional TV networks.
The analyst flagged the <a target="_blank" href="https://www.benzinga.com/media/24/12/42701434/netflixs-nfl-debut-brings-record-streams-but-lags-traditional-tv-report" rel="noreferrer noopener">drop in domestic ratings</a> year-on-year as expected.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42675098/netflix-takes-vmware-to-court-over-patent-infringement-claims" rel="noreferrer noopener">Broadcom and Netflix Clash Over Patent Disputes Ahead of 2025 Trial</a>
Netflix tapped Nielsen for average minute audience domestic ratings that were 24.1 million for the first game, Chief-Steelers, and 24.3 million for the Ravens-Texans match, a Ravens blowout win (that featured the Beyonce halftime show, which reached peak viewership of over 27 million.
By comparison, last year, the Christmas Day tripleheader on TV drew 29.6 million viewers on CBS, 29 million on Fox, and 27.1 million on ESPN and ABC.
So, the Netflix games did not repeat the Tyson and Paul boxing match spectacle, which drove much more viewership than anyone expected (Netflix reported 108 million globally for the boxing match).
Related Read: <a target="_blank" href="https://www.benzinga.com//node/42492251" rel="noreferrer noopener">Netflix CEO Says Paul-Tyson Fight &#8216;Really Phenomenal,&#8217; Strong Demand For NFL Game Advertising</a>
The NFL game&#8217;s audience was consistent with expectations for a typical dip in streaming versus TV.
Crockett noted that Netflix&#8217;s international numbers will come out on December 31 as a meaningful step up.
The analyst found Netflix&#8217;s P&amp;L as constructive as it came close to covering the $75 million it paid in license fees for each game, plus other expenses (Beyonce reports speculating a $20 million cost) with ad sales.
Still, the economics look better for Netflix than TV, which licenses a full season of NFL games, looks to use the games to drive up retransmission and affiliate fees, and sees advertising covering only a portion of the license costs.
Price Actions: NFLX stock is down 0.30% at $904.82 at last check Monday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/24/12/42667652/nvidias-advanced-ai-tech-powers-olympian-motors-new-electric-vehicle-platform" target="_blank" rel="noreferrer noopener">Nvidia&#8217;s Advanced AI Tech Powers Olympian Motors&#8217; New Electric Vehicle Platform</a></li>
</ul>
Photo via Shutterstock.

Analyst Color

Entertainment

Sports

General

AMZN

NFLX

Netflix's NFL Push Signals Shift In Sports Streaming Landscape, Analyst Says

Deep-pocketed investors have adopted a bullish approach towards Cleanspark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CLSK usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 56 extraordinary options activities for Cleanspark. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 46% leaning bullish and 37% bearish. Among these notable options, 17 are puts, totaling $1,518,546, and 39 are calls, amounting to $1,967,559.
<h3>Projected Price Targets</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $37.0 for Cleanspark over the last 3 months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Cleanspark stands at 7574.84, with a total volume reaching 62,696.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Cleanspark, situated within the strike price corridor from $5.0 to $37.0, throughout the last 30 days.
<h3>Cleanspark Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735580729_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLSK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$28.3</td>
<td>$28.2</td>
<td>$28.2</td>
<td>$37.00</td>
<td>$908.0K</td>
<td>7.5K</td>
<td>322</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$0.97</td>
<td>$0.95</td>
<td>$0.96</td>
<td>$14.00</td>
<td>$166.9K</td>
<td>6.6K</td>
<td>3.8K</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$1.07</td>
<td>$1.0</td>
<td>$1.04</td>
<td>$30.00</td>
<td>$125.7K</td>
<td>9.3K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$5.95</td>
<td>$5.7</td>
<td>$5.75</td>
<td>$5.00</td>
<td>$112.7K</td>
<td>4.2K</td>
<td>424</td>
</tr>
<tr>
<td>CLSK</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$0.82</td>
<td>$0.78</td>
<td>$0.79</td>
<td>$37.00</td>
<td>$91.2K</td>
<td>126.1K</td>
<td>4.8K</td>
</tr>
</tbody>
</table>

<h3>About Cleanspark</h3>
Cleanspark Inc is a bitcoin mining company. Through CleanSpark, Inc., and the Company's wholly owned subsidiaries, the company mines bitcoin. The company entered the bitcoin mining industry through its acquisition of ATL. Bitcoin mining is the sole reportable segment of the company.
Following our analysis of the options activities associated with Cleanspark, we pivot to a closer look at the company's own performance.
<h3>Present Market Standing of Cleanspark</h3>
<ul>
<li>Currently trading with a volume of 15,479,491, the CLSK's price is down by -3.78%, now at $9.41. </li>
<li>RSI readings suggest the stock is currently may be oversold.</li>
<li>Anticipated earnings release is in 38 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Cleanspark, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

CLSK

What the Options Market Tells Us About Cleanspark

Financial giants have made a conspicuous bullish move on NIO. Our analysis of options history for NIO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) revealed 13 unusual trades.
Delving into the details, we found 38% of traders were bullish, while 38% showed bearish tendencies. Out of all the trades we spotted, 8 were puts, with a value of $944,630, and 5 were calls, valued at $192,590.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $4.0 to $10.0 for NIO over the recent three months. 
<h3>Insights into Volume &amp; Open Interest</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for NIO's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across NIO's significant trades, within a strike price range of $4.0 to $10.0, over the past month.
<h3>NIO Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735580724_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$6.0</td>
<td>$5.85</td>
<td>$5.95</td>
<td>$10.00</td>
<td>$291.5K</td>
<td>12.9K</td>
<td>1.0K</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$6.05</td>
<td>$5.95</td>
<td>$6.0</td>
<td>$10.00</td>
<td>$255.0K</td>
<td>12.9K</td>
<td>433</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$5.7</td>
<td>$5.6</td>
<td>$5.62</td>
<td>$10.00</td>
<td>$92.7K</td>
<td>356</td>
<td>165</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$2.61</td>
<td>$2.59</td>
<td>$2.61</td>
<td>$7.00</td>
<td>$78.3K</td>
<td>6.1K</td>
<td>600</td>
</tr>
<tr>
<td>NIO</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>04/17/25</td>
<td>$5.65</td>
<td>$5.55</td>
<td>$5.6</td>
<td>$10.00</td>
<td>$75.6K</td>
<td>356</td>
<td>300</td>
</tr>
</tbody>
</table>

<h3>About NIO</h3>
Nio is a leading electric vehicle maker, targeting the premium segment. Founded in November 2014, Nio designs, develops, jointly manufactures, and sells premium smart electric vehicles. The company differentiates itself through continuous technological breakthroughs and innovations such as battery swapping and autonomous driving technologies. Nio launched its first model, its ES8 seven-seater electric SUV, in December 2017, and began deliveries in June 2018. Its current model portfolio includes midsize to large sedans and SUVs. It sold over 160,000 EVs in 2023, accounting for about 2% of the China passenger new energy vehicle market.
After a thorough review of the options trading surrounding NIO, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>NIO's Current Market Status</h3>
<ul>
<li>Trading volume stands at 20,370,947, with NIO's price down by -1.12%, positioned at $4.43.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 64 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for NIO, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

What the Options Market Tells Us About NIO

Whales with a lot of money to spend have taken a noticeably bearish stance on CrowdStrike Holdings.
Looking at options history for CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>) we detected 46 trades.
If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 45% with bearish.
From the overall spotted trades, 15 are puts, for a total amount of $1,210,405 and 31, calls, for a total amount of $2,745,207.
<h3>Predicted Price Range</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $210.0 to $460.0 for CrowdStrike Holdings over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for CrowdStrike Holdings's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of CrowdStrike Holdings's whale trades within a strike price range from $210.0 to $460.0 in the last 30 days. 
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1735580719_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$124.3</td>
<td>$122.5</td>
<td>$124.3</td>
<td>$290.00</td>
<td>$459.9K</td>
<td>136</td>
<td align="right">37</td>
</tr>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$46.15</td>
<td>$43.85</td>
<td>$45.06</td>
<td>$390.00</td>
<td>$351.4K</td>
<td>186</td>
<td align="right">93</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/18/26</td>
<td>$124.3</td>
<td>$122.55</td>
<td>$124.3</td>
<td>$290.00</td>
<td>$285.8K</td>
<td>136</td>
<td align="right">69</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$53.55</td>
<td>$53.55</td>
<td>$53.55</td>
<td>$300.00</td>
<td>$267.7K</td>
<td>426</td>
<td align="right">51</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$19.0</td>
<td>$18.75</td>
<td>$19.0</td>
<td>$380.00</td>
<td>$228.0K</td>
<td>1.3K</td>
<td align="right">142</td>
</tr>
</tbody>
</table>

<h3>About CrowdStrike Holdings</h3>
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.
Having examined the options trading patterns of CrowdStrike Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is CrowdStrike Holdings Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 900,622, the CRWD's price is down by -0.96%, now at $351.57. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 64 days.</li>
</ul>
<h3>What The Experts Say On CrowdStrike Holdings</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $420.75.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Goldman Sachs has decided to maintain their Buy rating on CrowdStrike Holdings, which currently sits at a price target of $415. 
&#x2A; An analyst from Stifel persists with their Buy rating on CrowdStrike Holdings, maintaining a target price of $400. 
&#x2A; Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for CrowdStrike Holdings, targeting a price of $450. 
&#x2A; An analyst from JP Morgan persists with their Overweight rating on CrowdStrike Holdings, maintaining a target price of $418. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest CrowdStrike Holdings options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

CRWD

Market Whales and Their Recent Bets on CRWD Options

IPO Roundup: Amer Sports, FibroBiologics, and more

In 2023, there were 154 IPOs on the U.S. stock market. Here is a brief look at some of the worst-performing initial public offerings from last year.

The Worst-Performing U.S. IPOs Of 2023

Hanryu Holdings, Inc. (HRYU) has released an update. Hanryu Holdings, Inc. has been notified by Nasdaq that its stock price has fallen below the $1...

Hanryu Holdings Faces Nasdaq Delisting Over Low Stock Price

Hanryu Holdings, Inc. (HRYU) has provided an update. Hanryu Holdings, Inc. is in the midst of executive turmoil as TaeHoon Kim, the Chief Technolog...

Hanryu Holdings Faces Executive Leadership Dispute

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Pre-market stock movers are worth diving into as we check out all of the hottest news affecting shares on Tuesday morning!



<a href="https://investorplace.com/stock-types/meme-stocks/">Meme stocks</a> continue to rally, companies release earnings reports, and more market news has shares moving today.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>AMC Entertainment (NYSE:<a href="https://investorplace.com/stock-quotes/amc-stock-quote/">AMC</a>) stock is rocketing more than 59% as <a href="https://twitter.com/TheRoaringKitty">Roaring Kitty&rsquo;s return</a> continues to bolster the shares.</li>



<li>GameStop (NYSE:<a href="https://investorplace.com/stock-quotes/gme-stock-quote/">GME</a>) shares are soaring over 54% alongside the return of Roaring Kitty.</li>



<li>MicroCloud Hologram (NASDAQ:<a href="https://investorplace.com/stock-quotes/holo-stock-quote/">HOLO</a>) stock is surging 41% with heavy pre-market trading.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are gaining more than 34% with strong early morning trading today.</li>



<li>Warrantee (NASDAQ:<a href="https://investorplace.com/stock-quotes/wrnt-stock-quote/">WRNT</a>) stock is increasing over 27% without any clear news this morning.</li>



<li>BlackBerry (NYSE:<a href="https://investorplace.com/stock-quotes/bb-stock-quote/">BB</a>) shares are rising more than 24% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318312931&amp;type=PDF&amp;symbol=BB&amp;cdn=4b26c072318efaefdc3ba22b7b5e8deb&amp;companyName=BlackBerry+Limited&amp;formType=DEFA14A&amp;formDescription=Additional+proxy+soliciting+materials+-+definitive&amp;dateFiled=2024-05-13">shareholder meeting update</a>.</li>



<li>Rent the Runway (NASDAQ:<a href="https://investorplace.com/stock-quotes/rent-stock-quote/">RENT</a>) stock is climbing over 19% this morning.</li>



<li>SunPower (NASDAQ:<a href="https://investorplace.com/stock-quotes/spwr-stock-quote/">SPWR</a>) shares are heading more than 19% higher <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318314743&amp;type=PDF&amp;symbol=SPWR&amp;cdn=ecf4fe81973e2491082785bf9c740edb&amp;companyName=SunPower+Corporation&amp;formType=NT+10-Q&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-Q+or+10-QSB&amp;dateFiled=2024-05-13">despite a delayed filing</a>.</li>



<li>AMTD Digital (NYSE:<a href="https://investorplace.com/stock-quotes/hkd-stock-quote/">HKD</a>) stock is jumping over 18% on Tuesday morning.</li>



<li>Koss (NASDAQ:<a href="https://investorplace.com/stock-quotes/koss-stock-quote/">KOSS</a>) shares are up more than 16% <a href="https://investorplace.com/2024/05/blast-from-the-past-former-meme-koss-stock-soars-on-roaring-kitty-news/">alongside the meme stock rally</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>Inotiv (NASDAQ:<a href="https://investorplace.com/stock-quotes/notv-stock-quote/">NOTV</a>) stock is plummeting over 34% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318314218&amp;type=PDF&amp;symbol=NOTV&amp;cdn=ebe87b345e7637122dc6a4d631ded890&amp;companyName=Inotiv+Inc.&amp;formType=NT+10-Q&amp;formDescription=Notification+of+inability+to+timely+file+Form+10-Q+or+10-QSB&amp;dateFiled=2024-05-13">alongside preliminary earnings</a>.</li>



<li>Augmedix (NASDAQ:<a href="https://investorplace.com/stock-quotes/augx-stock-quote/">AUGX</a>) shares are diving close to 33% after releasing its <a href="https://www.nasdaq.com/press-release/augmedix-delivers-40-revenue-growth-for-first-quarter-of-2024-2024-05-13">latest earnings report</a>.</li>



<li>Scorpius (NYSEMKT:<a href="https://investorplace.com/stock-quotes/scpx-stock-quote/">SCPX</a>) stock is tumbling more than 22% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318315844&amp;type=PDF&amp;symbol=SCPX&amp;cdn=2f4148150720f83231bf9f50680f426c&amp;companyName=Scorpius+Holdings+Inc.&amp;formType=EFFECT&amp;formDescription=Notice+of+Effectiveness&amp;dateFiled=2024-05-13">with a public offering</a>.</li>



<li>Akoya Biosciences (NASDAQ:<a href="https://investorplace.com/stock-quotes/akya-stock-quote/">AKYA</a>) shares are taking an over 19% beating after <a href="https://www.marketwatch.com/story/shares-of-akoya-biosciences-drop-after-1q-earnings-revenue-outlook-miss-c9dded98?mod=newsviewer_click">missing Q1 estimates</a>.</li>



<li>Eastside Distilling (NASDAQ:<a href="https://investorplace.com/stock-quotes/east-stock-quote/">EAST</a>) stock is dropping more than 18% after <a href="https://www.nasdaq.com/press-release/eastside-distilling-reports-first-quarter-2024-financial-results-2024-05-13">posting its Q1 results</a>.</li>



<li>Nuzee (NASDAQ:<a href="https://investorplace.com/stock-quotes/nuze-stock-quote/">NUZE</a>) shares are sliding over 14% this morning.</li>



<li>Terran Orbital (NYSE:<a href="https://investorplace.com/stock-quotes/llap-stock-quote/">LLAP</a>) stock is falling more than 14% with its <a href="https://www.businesswire.com/news/home/20240514904938/en/Terran-Orbital-Reports-First-Quarter-2024-Financial-Results">Q1 earnings report</a>.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) shares are slipping over 13% this morning.</li>



<li>Invo Bioscience (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/">INVO</a>) stock is dipping more than 12% today.</li>



<li>Intelligent Living (NASDAQ:<a href="https://investorplace.com/stock-quotes/ilag-stock-quote/">ILAG</a>) shares close out our pre-market stock movers down over 12% today.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/05/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-tuesday-may-14th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Hanryu Holdings received notice of non-compliance from Nasdaq

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
It&rsquo;s time to dive into the biggest pre-market stock movers as we check out all of the latest news happening on Wednesday morning!



Moving stocks this morning are patent news, a new investment, proposed public offerings and more.



Let&rsquo;s get into that news below!



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li>Syntec Optics (NASDAQ:<a href="https://investorplace.com/stock-quotes/optx-stock-quote/">OPTX</a>) stock is rocketing more than 248% alongside heavy pre-market trading.</li>



<li>Anew Medical (NASDAQ:<a href="https://investorplace.com/stock-quotes/wena-stock-quote/">WENA</a>) shares are soaring over 75% after <a href="https://www.nasdaq.com/press-release/anew-medical-inc-secures-key-patent-europe-human-klotho-gene-rna-slice-variant-and">securing a key patent in Europe</a>.</li>



<li>Volcon (NASDAQ:<a href="https://investorplace.com/stock-quotes/vlcn-stock-quote/">VLCN</a>) stock is surging more than 36% as it <a href="https://investorplace.com/2024/06/why-is-volcon-vlcn-stock-up-60-today/">continues yesterday&rsquo;s rally</a>.</li>



<li>Rivian Automotive (NASDAQ:<a href="https://investorplace.com/stock-quotes/rivn-stock-quote/">RIVN</a>) shares are gaining over 36% on a <a href="https://www.nytimes.com/2024/06/25/business/volkswagen-rivian-vw-investment.html">$5 billion investment</a>.</li>



<li>China Natural Resources (NASDAQ:<a href="https://investorplace.com/stock-quotes/chnr-stock-quote/">CHNR</a>) stock is increasing more than 32% with strong trading this morning.</li>



<li>Savara (NASDAQ:<a href="https://investorplace.com/stock-quotes/svra-stock-quote/">SVRA</a>) shares are rising over 26% on a <a href="https://seekingalpha.com/news/4119362-savara-stock-surges-trial-win-lead-asset?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain">positive clinical trial</a>.</li>



<li>Talphera (NASDAQ:<a href="https://investorplace.com/stock-quotes/tlph-stock-quote/">TLPH</a>) stock is heading more than 21% higher on Wednesday morning.</li>



<li>eFFECTOR Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/eftr-stock-quote/">EFTR</a>) shares are climbing over 18% even as it plans to <a href="https://finance.yahoo.com/news/effector-therapeutics-announces-wind-down-110000717.html">wind down operations</a>.</li>



<li>Golden Matrix (NASDAQ:<a href="https://investorplace.com/stock-quotes/gmgi-stock-quote/">GMGI</a>) stock is jumping more than 15% today.</li>



<li>Faraday Future (NASDAQ:<a href="https://investorplace.com/stock-quotes/ffie-stock-quote/">FFIE</a>) shares are up over 14% <a href="https://investorplace.com/2024/06/faraday-future-stock-shocker-from-ev-maker-to-china-u-s-auto-middleman/">on survival plans</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li>NextTrip (NASDAQ:<a href="https://investorplace.com/stock-quotes/ntrp-stock-quote/">NTRP</a>) stock is diving more than 24% without any recent news to report.</li>



<li>GRI Bio (NASDAQ:<a href="https://investorplace.com/stock-quotes/gri-stock-quote/">GRI</a>) shares are tumbling over 15% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318415310&amp;type=PDF&amp;symbol=GRI&amp;cdn=40db9b65c5660c095bf51f08f72c725f&amp;companyName=GRI+Bio+Inc.&amp;formType=S-1%2FA&amp;formDescription=%5BAmend%5D+General+form+for+registration+of+securities+under+the+Securities+Act+of+1933&amp;dateFiled=2024-06-26">proposed public offering</a>.</li>



<li>Taysha Gene Therapies (NASDAQ:<a href="https://investorplace.com/stock-quotes/tsha-stock-quote/">TSHA</a>) stock is taking a 14% beating on <a href="https://www.nasdaq.com/press-release/taysha-gene-therapies-announces-proposed-public-offering-common-stock-and-pre-funded">public offering plans</a>.</li>



<li>Oblong (NASDAQ:<a href="https://investorplace.com/stock-quotes/oblg-stock-quote/">OBLG</a>) shares are sliding more than 12% despite a lack of news this morning.</li>



<li>Hanryu (NASDAQ:<a href="https://investorplace.com/stock-quotes/hryu-stock-quote/">HRYU</a>) stock is decreasing over 11% on Wednesday.</li>



<li>Hamilton Beach Brands (NYSE:<a href="https://investorplace.com/stock-quotes/hbb-stock-quote/">HBB</a>) shares are dropping more than 10% today.</li>



<li>GlycoMimetics (NASDAQ:<a href="https://investorplace.com/stock-quotes/glyc-stock-quote/">GLYC</a>) stock is falling over 10% <a href="https://finance.yahoo.com/news/senior-vp-chief-medical-officer-100744620.html">despite insider buying</a>.</li>



<li>Geovax Labs (NASDAQ:<a href="https://investorplace.com/stock-quotes/govx-stock-quote/">GOVX</a>) shares are slipping more than 9% today.</li>



<li>Concord Medical Services (NYSE:<a href="https://investorplace.com/stock-quotes/ccm-stock-quote/">CCM</a>) stock is dipping over 9% this morning.</li>



<li>DermTech (NASDAQ:<a href="https://investorplace.com/stock-quotes/dmtk-stock-quote/">DMTK</a>) shares close out our pre-market stock movers down more than 9% as they <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318404814&amp;type=PDF&amp;symbol=DMTK&amp;cdn=2f95604b7d0b2db1ef0d52c1cc04ae14&amp;companyName=DermTech+Inc&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-06-20">prepare for delisting tomorrow</a>.</li>
</ol>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/06/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-june-26th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

AKYA

AUGX

BTSG

BVFL

CGON

CHNR

CTNT

DMTK

DOCO

EAST

EFTR

FBLG

FFIE

GMGI

GOVX

HOLO

INTJ

INVO

KOSS

LLAP

LSDI

MGRX

MIRA

NOTV

NTRP

NUZE

OBLG

OPTX

PMNT

PXDT

RENT

SCPX

SPWR

SRFM

SUBL

SVRA

TLPH

TSHA

UCAR

VLCN

WENA

WRNT

ZJYL

Press Releases

Hanryu Holdings, Inc. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq

Legal

Comments

(HRYU) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga